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Abstract 
 
Background: Chronic kidney disease (CKD) is a silent clinical condition associated with 
adverse comorbidity and high cardiovascular disease (CVD) risk. An inverse relationship 
with body mass index (BMI) and mortality has been demonstrated in hemodialysis patients. 
However, it is unclear if this risk-factor paradox is evident in non-dialysis CKD patients. The 
aims of this study were to explore the relationship between, nutritional status, markers of 
inflammation, autonomic and cardiac function with BMI. Longitudinal follow-up explored 
the relationship between BMI and all-cause mortality.  
 
Methods: 211-consecutive CKD patients referred for dobutamine stress echocardiography to 
detect or exclude myocardial ischemia were recruited. BMI, albumin, C-reactive protein 
(CRP) and haemoglobin (Hb) were recorded as markers of nutritional and inflammatory 
status. Left ventricular ejection fraction (LVEF) and heart rate variability (HRV) as an 
indicator of cardiac function was recorded. All subjects were followed prospectively until 
November 2014 and study end-point was all-cause mortality. 
 
Results: BMI was inversely associated with CKD status. After covariate adjustment, this 
association remained. During a mean follow-up period of 3.3±0.9 years there were 35 deaths 
(17%). BMI was inversely associated with all-cause mortality (HR 0.81, 95% CI 0.71-0.9). 
Other important independent predictors of mortality were heart rate variability (HR 0.98, 
95% CI 0.97-0.99), myocardial ischemia (HR 1.37, 95% CI 1.17-1.81), and albumin (HR 
0.86, 95% CI 0.81-0.92).  
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Conclusions: The presence of a BMI paradox exists in non-dialysis CKD patients. This risk-
factor paradox was an independent predictor of all-cause mortality and may have significant 
clinical implications relevant to screening, assessment and treatment and requires further 
study.  
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1: Introduction 
 
Several epidemiological studies have identified obesity as an established risk factor for 
cardiovascular disease and all-cause mortality. As such, the World Health Organisation 
(WHO) has produced guidelines on body mass index (BMI, in kg·m2) and its relationship 
with health risks from obesity-related conditions such as type-2 diabetes (T2DM), CVD, and 
death [1]. Normal weight is deemed 18.5-24.9 kg·m2, overweight, 25-29.9 kg·m2 and obese 
≥30kg·m2 [1]. However, the use of BMI screening alone is problematic based upon current 
research, as there is evidence of a ‘BMI paradox’. Recent research demonstrated that 
compared to normal weight (18.5-24.9 kg·m2), grade 1 obesity (30-34.9 kg·m2) was not 
associated with higher mortality and overweight (25-29.9 kg·m2) was associated with 
significantly lower all-cause mortality in the general population [2]. Furthermore, in clinical 
populations the BMI paradox is a well-known phenomenon, especially in end-stage CKD and 
chronic heart failure (CHF) patients, whereby high BMI has a protective effect on mortality 
risk [3]. The reasons for this risk-factor paradox are not completely understood. 
 
Chronic kidney disease (CKD) is a serious medical condition, frequently unrecognised and 
associated with increased risks of morbidity and mortality, in particular cardiovascular 
disease (CVD) [4-8]. Its development and pathology is believed to be due to many different 
factors including exposure to obesity and metabolic syndrome (MetS) [6, 9-11]. Worsening 
kidney function is associated with insulin resistance, inflammation, anaemia, acidosis, 
anorexia, hypermetabolism, increased protein degradation and muscle wasting [6, 12-16]. In 
severe CKD a relationship was identified between malnutrition, inflammation and 
atherosclerosis (termed the ‘MIA syndrome’), which was associated with poor outcome and a 
BMI/obesity paradox [15-17].  
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The International Society for Renal Nutrition and Metabolism (ISRNM) developed a 
nomenclature and diagnostic criteria for ‘protein-energy wasting’ (PEW) in CKD [13]. Other 
definitions have been developed for related conditions including ‘cachexia’ [18] and 
‘sarcopenia’ [19], and it is quite feasible that many patients with CKD may suffer from 
significant weight loss, reduced muscle mass/sarcopenia, inflammation and meet criteria for 
PEW, cachexia and sarcopenia, which may increase mortality risk. Of the differing 
definitions, unintentional weight loss, BMI (e.g., <23 kg·m2 ISRNM [13] and <20-22 kg·m2 
[18]), plasma albumin (e.g., <38 mg·L-1 ISRNM [13] and <32 mg·L-1 [18]) and inflammation 
(e.g., CRP >5.0 mg·L-1 [18]) have high importance in diagnosis. Albumin and CRP in 
particular, have been shown to be powerful predictors of CVD and mortality, and specifically 
within CKD populations (even in earlier CKD stages, II-IV) [20, 21].  
 
Cardiac dysfunction (e.g., myocardial ischemia and reduced left ventricular ejection fraction 
(LVEF)) is common in CKD. Further, heart rate variability (HRV), a non-invasive marker of 
cardiac autonomic function, has proven to be a novel predictor of mortality in CKD patients 
[22]. HRV measures have been found to inversely correlate with inflammation [23] and 
positively correlate with neurohormonal activation (epinephrine and norepinephrine) and 
cachexia/wasting in CHF patients [24, 25].  
 
The importance of BMI and these different factors in earlier stages of CKD is unknown as is 
their relationship with long-term mortality risk. This study aimed to explore the relationship 
between BMI and measures of nutritional status, inflammation and cardiac autonomic 
function in non-dialysis CKD patients referred for dobutamine stress echocardiography 
(DSE) and their relative abilities to predict long-term all-cause mortality. 
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2: Methods 
 
2.1: Participants 
 
This was a prospective observational study of consecutive non-dialysis CKD patients 
clinically referred for an outpatient DSE between December 2010 and June 2011. Two 
hundred and eleven CKD patients volunteered to participate in the study. Exclusion criteria 
were age <18 years, unstable angina, dialysis patients, patients with preserved kidney 
function, non-fasted patients, patients with acute illness at the time of recruiting, congenital 
heart disease, pregnant women, and inability to provide consent. All patients provided 
informed consent and the study had approval from the local ethics committee.  
 
Study entry was at the time of the patient’s DSE. At this stage a structured history and 
medical record review was performed to document symptoms, medical history, cardiac risk 
factors, and previous cardiac events and procedures. The patient’s height and weight were 
recorded in order to calculate BMI.  
 
2.2: Laboratory Measurements 
 
Fasting whole blood samples were drawn from all patients via vena puncture. This was 
performed according to the local NHS trust hospital guidelines. All samples were 
immediately sent to the laboratory for processing. In total 50 ml of blood per patient was 
required. Blood sample concentrations of albumin, C-reactive protein (CRP), total 
cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, 
triglycerides, creatinine, hemoglobin, potassium, sodium, and urea were measured.  
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Estimated glomerular filtration rate (eGFR) was calculated using the four-variable 
modification of diet in renal disease (MDRD) formula [26] as follows: GFR = 186.3 X 
(serum creatinine-1.154) X (age-0.203) X 1.212 (if black) X 0.742 (if female). Serum creatinine 
is measured in mg·dL-1, age is in years, and GFR is in ml·min-1·1.73m2. The patients were 
then divided according to their eGFR where 60-89 is mild CKD (stage II), 30-59 moderate 
CKD (stage III), 15-29 severe CKD (stage IV) and <15 ml·min-1·1.73m2 is end stage kidney 
failure (stage V). 
 
2.3: Autonomic Assessment 
 
The Task Force® Monitor (TFM) (CNSystems, Graz, Austria) was used for the continuous 
non-invasive beat-to-beat monitoring and real time calculation of cardiac autonomic function. 
The TFM uses an integrated two-channel ECG for R-R interval determination, which was 
instantaneously calculated as the difference between successive R-R peaks. Real-time beat-
to-beat HRV was calculated using power spectral analysis and applying an autoregressive 
model [27]. Specific frequencies within the power spectrum of HRV have been previously 
used to quantify autonomic nervous control of the cardiovascular system. Low frequency 
(0.04 – 0.15 Hz) HRV is considered a marker of sympathetic activity on the heart [28] and 
high frequency (0.15 – 0.4 Hz) HRV is considered a marker of parasympathetic cardiac 
modulation [28]. Parameters of HRV were automatically calculated by the TFM and 
expressed in absolute (ms2) and normalised units (nu). The normalisation of the frequency 
components of HRV has proven crucial to the interpretation of data [29] and the TFM 
automatically calculates this by dividing the absolute power of each oscillatory component by 
total power minus the very low frequency and multiplying by 100. The ratio of LF-to-HF for 
HRV is an accepted index of cardiac sympathovagal balance [30].  
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2.4: Cardiac Stress Test 
 
DSE was the test selected for the non-invasive evaluation of ischemic heart disease and 
assessment of global cardiac structure and function. Left ventricular ejection fraction (LVEF) 
was determined by the modified biplane Simpson’s rule, with measurements averaged over 
three cardiac cycles. Patients underwent a standard DSE protocol [31] with stepwise infusion 
of dobutamine in 3-minute stages of 10, 20, 30, 40 gkg-1min-1. -blocker therapy was 
stopped 72-hours before DSE and patients were fasted as per protocol. Based on the 
myocardial response during DSE, patients were categorised as non-ischaemic (normal) or 
ischaemic. In the normal response, a segment is normokinetic or hypokinetic at rest with an 
overall increase in wall motion during stress. In the ischaemic response, a segment worsens 
its function during stress from normokinesis to hypokinesis, akinesis, or dyskinesis. 
 
2.5: End Point Definition 
 
The principle end-point of interest for this analysis was all-cause mortality, with patients 
censored at the time of the last follow-up. Follow-up data was collated by contacting patients 
or a family member, general practitioners, and reviewing hospital records. The date of the last 
review or consultation was used to calculate the duration of follow-up through to November 
2014. 
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2.6: Data Analysis 
 
Continuous variables were expressed as mean±standard deviation and categorical variables as 
n (%). Group comparisons were based on 2-sample t test for continuous variables and 2 test 
was used for group comparisons among categorical variables.  
 
Logistic regression was used to assess CKD status as a categorical variable (mild, moderate 
and severe) and its association with BMI (dichotomised into BMI <25 kg·m2 and ≥25 kg·m2). 
A multivariate model was then constructed to ascertain variables associated with BMI. For 
model building, demographic, clinical history, laboratory measures, cardiac autonomic, and 
echocardiographic parameters were considered. Stepwise forward selection logistic 
regression was performed with factors added at the 0.15 level of significance.  
 
Multivariable adjusted Cox proportional hazard models were constructed to ascertain 
predictors of all-cause mortality. BMI was used as a continuous variable in the Cox model. 
For model building, demographic, clinical history, laboratory measures, cardiac autonomic 
and echocardiographic parameters were evaluated for their association with mortality. 
Forward stepwise selection procedures were used to compare models for goodness-of-fit and 
a P-value <0.15 was used for retention in the final model. Hazard ratios (HR) and 
corresponding 95% confidence intervals (CI) are reported. Survival was further analyzed by 
Kaplan-Meier methods, with cumulative event curves constructed and compared using the 
log-rank test with a P value <0.05 considered statistically significant. BMI was stratified 
according <25 and ≥25 kg·m2.  
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All analysis was conducted using the statistical package for social sciences (SPSS 21, release 
version of SPSS for Windows; SPSS Inc., Chicago IL, USA). 
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3: Results 
 
The descriptive characteristics of the study population according to BMI <25 kg·m2 and ≥25 
kg·m2 are shown in Table 1. Of the clinical history parameters, the prevalence of prior 
percutaneous coronary intervention (p=0.002) significantly differed between groups. Of the 
cardiac autonomic parameters, HRV (p=0.03), LFnu (p=0.02), HFnu (p=0.02) and LF/HF 
ratio (p=0.01) significantly differed between groups. Of the laboratory parameters, Albumin 
(p=0.02), CRP/albumin ratio (p=0.04), cholesterol (p=0.03), creatinine (p=0.003), eGFR 
(p=0.04), haemoglobin (p=0.01), low-density lipoprotein (p=0.03), sodium (p=0.001), and 
urea (p=0.04) significantly differed between groups. There were no significant differences in 
echocardiographic parameters.  
 
Table 2 shows the Odds Ratios for the association with a BMI <25 kg·m2. The unadjusted 
model (model 1) showed a significant inverse relationship between the odds of being a BMI 
<25 kg·m2 and moderate (OR 1.67; 95% CI 1.56-5; p=0.02) and severe (OR 2.4; 95% CI 
1.16-9.9; p=0.03) CKD status. Model 2 shows the Odds Ratios for the significant 
determinants in which BMI was adjusted using stepwise forward selection logistic regression. 
Albumin and LF/HF ratio emerged as significant predictors of a BMI <25 kg·m2. CKD status 
remained significantly and inversely associated with a BMI <25 kg·m2. 
 
3.1: Survival Analysis 
 
The primary end-point of all-cause mortality was observed in 35 (16.6%) patients over a 4-
year follow-up period. Mean whole group eGFR was 61.5±19.6 ml·mim-1·1.73m2. There was 
a significant difference (p<0.001) in eGFR between those that died (46.8±15.9 ml·mim-
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1
·1.73m2) and survived (64.4±19.0 ml·mim-1·1.73m2). BMI was 23.8±2.3 kg·m2 (normal 
weight) in the patients who died compared to 28.7±4.7 kg·m2 (overweight), in those that 
survived (p<0.001) (Supplementary Table 1). Of the patients alive (n=176), 2.8% (n=5) were 
stage V and 1.1% (n=2) stage IV; of the deceased group 2.9% (n=1) were stage V and 14.3% 
(n=5) stage IV.  
 
The unadjusted Kaplan-Meier survival curve for the cumulative freedom from all-cause 
mortality, dichotomized according to BMI (<25 and ≥25 kg·m2) is presented in figure 1. The 
differences amongst the curves are significant (p<0.001). Following adjusted multivariate 
Cox regression; BMI used as a continuous variable (HR 0.81; 95% CI 0.71-0.9; p<0.001), 
HRV (HR 0.98; 95% CI 0.97-0.99; p=0.02), albumin (HR 0.86; 95% CI 0.81-0.92; p<0.001), 
CRP (HR 1.14; 95% CI 1.11-1.34; p=0.04) and presence of myocardial ischemia (HR 1.37; 
95% CI 1.17-1.81; p=0.01) were independently associated with all-cause mortality (Table 3).  
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4: Discussion  
 
The relative ability to identify individuals with mild-moderate CKD at greater risk of 
morbidity and mortality has high clinical importance. This study demonstrated an inverse 
relationship between the prevalence of CKD and BMI. Furthermore, in contrast to 
observations from the general population, overweight and obese CKD patients had a lower 
adjusted risk of all-cause mortality compared to normal weight CKD patients. This is the first 
study to identify a BMI risk paradox in predominantly mild-moderate CKD patients (mean 
group eGFR: 61.5±19.6 ml·min-1·1.73m2) referred for a cardiac investigation. The obesity 
paradox has been observed previously in the elderly [32], and in end stage kidney disease 
[17] and CHF patients [3]. The mechanisms responsible for this observation are not 
completely clear, but may in part be due to inflammation, malnutrition, cardiac dysfunction, 
heightened sympathetic activity, oedema, and drug interactions.  
 
In this patient group, the acute phase proteins, albumin and CRP were measured and analysed 
to act as principle markers of inflammation, although it is understood that albumin is also a 
marker of nutritional status. Albumin was 33.7±5.5 g·L-1 for those who died, which indicates 
hypoalbuminemia. The mean albumin levels were below the cut-point suggested by ISRNM 
to indicate PEW (38 g·L-1) and above Evans et al. (2008) for cachexia (32 g·L-1) [13, 18]. 
CRP was clinically significant for both dead and alive patients (i.e., >5 g·L-1). Multivariate 
Cox regression analysis showed that albumin and CRP were significant predictors of 
mortality. However, Albumin was the only marker significantly associated with a BMI <25 
kg·m2.  Inspection of other blood markers further indicates inflammation and metabolic 
dysfunction e.g., significantly lower Hb and higher urea in patients who died (Supplementary 
Table 1). Patients who died had an average Hb of 11.3±2.3 g·dL-1 indicating anemia risk (<12 
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g·dL-1), which is a hallmark of the ‘cardio-renal syndrome’ and is also utilised in the cachexia 
diagnosis algorithm [18, 33]. It is understood that inflammation itself promotes anemia, 
through causing erythropoietin resistance and would only worsen a systemic physiological 
situation of reduced kidney and cardiac function, e.g. through potential tissue hypoxia (36).  
 
DSE was utilised as a model to examine cardiac structure, function and presence or absence 
of myocardial ischemia. The presence of myocardial ischemia was significantly greater in 
CKD patients who died and LVEF was significantly reduced indicating greater cardiac 
dysfunction, which has been well characterised in this population. However, 
echocardiographic parameters were not significantly associated with a BMI <25 kg·m2, 
perhaps demonstrating that these are not mechanisms driving the BMI risk paradox. HRV 
was utilised as a marker of cardiac autonomic function and was a significant independent 
predictor of mortality. In addition a greater LF/HF ratio, which is an indicator of heightened 
sympathetic activity was significantly associated with a BMI <25 kg·m2. HRV parameters 
have been linked to the cardiac cachexia-wasting syndrome in CHF patients [24, 25] and may 
be one mechanism driving the BMI risk paradox in non-dialysis CKD patients.  
 
A hallmark of cachexia is the association of body wasting and muscle loss with 
neurohormonal activation, heightened circulating stress hormones; epinephrine, 
norepinephrine, cortisol and proinflammatory cytokines, as part of an acute phase response to 
illness [6, 12-14, 18, 24]. The loss of tissue is due to a combination of a reduction in 
appetite/anorexia, hypermetabolism, and increased cellular protein breakdown. This is a well-
known and common occurrence in CKD stage V and in dialysis patients; however, 
understanding the pathogenesis and trajectory within mild-moderate CKD is unknown. It 
could be hypothesised that patients in this study who showed clinically significant 
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inflammation (high CRP, low albumin), anemia (low Hb), and cardiac and autonomic 
dysfunction may have experienced detectable cachexia (measurable significant weight loss 
and skeletal muscle mass depletion) during the study follow-up period, which may have 
affected survival. Furthermore, these commonly associated alterations in body composition in 
diseases such as CKD and CHF (e.g. body protein tissue wasting and simultaneous oedema) 
may mask changes in overall BMI and could be one explanation for a BMI paradox. Future 
studies would be necessary to confirm this hypothesis and would need to include full body 
weight and body composition assessment throughout long-term follow-up. 
 
An important observation in this study was that the patients were predominantly of Asian 
ethnicity (n=118/211 56%). Within the United Kingdom (UK), the National Institute for 
Health and Clinical Excellence (NICE) has published numerous reports and clinical guidance 
on BMI, health risks and weight reduction. Recently, NICE has suggested that lower BMI 
thresholds (23 kg·m2 and 27.5 kg·m2 respectively) should be utilised to indicate greater risk 
of T2DM, CVD and death in black and Asian populations [34]. This could have important 
implications, since overweight and obese patients with mild-moderate CKD would usually be 
encouraged to undergo weight loss, as they would be deemed at higher risk. This study 
demonstrates that patients with a lower and normal BMI are at increased risk of all-cause 
mortality. Therefore, it is unclear whether or not a weight loss programme would be harmful 
without full clinical screening and understanding of the BMI paradox and any underlying 
metabolic and inflammatory disturbances in this patient population.  
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5: Limitations 
 
This was a small sample size single centre study and therefore there is potential for referral 
bias. In addition, the participants were a select group of non-dialysis CKD patients referred 
for a DSE and the findings may not be relevant to other CKD patients. Furthermore, the 
patient ethnicity was predominately of UK Indian Asian origin and the results may not be 
representative of other populations. Screening and assessments were performed once only 
and it is therefore unclear whether there were significant changes in variables during the 
follow-up period.  
 
6: Conclusion 
 
This study highlights the presence of a BMI paradox in non-dialysis CKD patients. This risk-
factor paradox was an independent predictor of all-cause mortality and may have significant 
clinical implications relevant to screening, assessment and treatment and requires further 
study.  
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Figure Legends 
 
Figure 1: Kaplan-Meier hazard curves dichotomized according to body mass index (<25 and 
≥25 kg·m2).  
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Table 1. Descriptive characteristics of the study population. 
Characteristics 
<25 kg·m2 ≥25 kg·m2 P 
(n = 63) (n = 148) Value 
Demographics    
 Age, y 63.9 ± 16.4 64.7 ± 14.3 0.2 
 Men 39 (61.9) 80 (54.1) 0.29 
 Ethnicity   0.78 
  Black 6 (9.5) 16 (10.8)  
  Caucasian 25 (39.7) 53 (35.8)  
  Indian Asian 32 (50.8) 79 (53.4)  
Clinical History    
 Hypertension 17 (27) 56 (37.8) 0.13 
 Diabetes mellitus 16 (25.4) 29 (19.6) 0.64 
 Hypercholesterolemia 19 (30.2) 51 (34.5) 0.54 
 Family history of cardiovascular disease 7 (11.1) 12 (8.1) 0.49 
 Prior myocardial infarction 4 (6.3) 12 (8.1) 0.7 
 Prior PCI 9 (14.3) 53 (35.8) 0.002 
 Prior CABGS 10 (15.9) 27 (18.2) 0.68 
Cardiac Autonomic Function    
 HRV total power spectrum (ms2) 1243 ± 1834 1932 ± 2185 0.03 
 LFnu RRI (%) 41.4 ± 21.3 28.6 ± 23.5 0.02 
 HFnu RRI (%) 58.6 ± 21.3 71.4 ± 23.5 0.02 
 VLF RRI (ms2) 175 ± 299 203 ± 262 0.73 
 LF RRI (ms2) 435 ± 712 554 ± 651 0.49 
 HF RRI (ms2) 626 ± 833 1234 ± 1354 0.84 
 LF/HF Ratio 0.91 ± 0.9 0.41 ± 0.5 0.01 
 BRS (ms·mmHg-1) 9.2 ± 10.7 10.1 ± 8.1  0.54 
Cardiac Stress Test    
 Left ventricular ejection fraction (%) 54.5 ± 9.8 55.9 ± 7.8 0.28 
 Myocardial ischemia 18 (28.6) 30 (20.3) 0.21 
Laboratory Values     
 Albumin (mg·L-1) 40.2 ± 5.4 42.1 ± 4.7 0.02 
 C-reactive protein (mg·L-1) 8.6 ± 3.8 8 ± 2.9 0.07 
 C-reactive protein /Albumin ratio 0.23 ± 0.12 0.19 ± 0.09 0.04 
 Cholesterol (mmol·L-1) 3.82 ± 1 4.23 ± 1.1 0.03 
 Creatinine (mol·L-1) 133 ± 89 105 ± 45 0.003 
 eGFR (ml·mim-1·1.73m2) 57 ± 19.8 63 ± 19 0.04 
 Hemoglobin (g·dL-1) 12 ± 2 12.8 ± 1.8 0.01 
 HDL (mmol·L-1) 1.29 ± 0.4 1.39 ± 0.5 0.31 
 LDL (mmol·L-1) 1.8 ± 0.8 2.1 ± 0.9 0.03 
 Potassium (mmol·L-1) 4.6 ± 0.5 4.6 ± 0.5 0.88 
 Sodium (mmol·L-1) 136 ± 4.4 139 ± 4.7 0.001 
 Triglyceride (mmol·L-1) 1.4 ± 0.7 1.5 ± 0.9 0.67 
 Urea (mmol·L-1) 9.2 ± 5.6 7.7 ± 4.2 0.04 
Note: PCI = Percutaneous coronary intervention; CABGS = Coronary artery bypass graft surgery; 
HRV = Heart rate variability; LFnu RRI = Low frequency normalized units RR interval; HFnu RRI = 
High frequency normalized units RR interval; VLFnu RRI = Very low frequency normalized units RR 
interval; LF RRI = Low frequency RR interval; HF RRI = High frequency RR interval; LF/HF Ratio 
= Low frequency/high frequency ratio; eGFR = Estimated glomerular filtration rate; HDL = High 
density lipoprotein; LDL = Low density lipoprotein. 
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Table 2. Odds ratios for the association with a BMI <25 kg·m2.  
 Model 1 Model 2 
Independent variable OR (95% CI) P OR (95% CI) P 
CKD     
 Mild 1 (reference)  1 (reference)  
 Moderate 1.67 (1.56-5) 0.02 1.12 (1.02-1.38) 0.02 
 Severe 2.4 (1.16-9.9) 0.03 1.15 (1.12-1.78) 0.02 
Albumin (mg·L-1)   0.95 (0.91-0.98) 0.04 
Creatinine (mol·L-1) 
  1.01 (0.91-1.19) 0.16 
LF/HF ratio   1.28 (1.19-1.67) 0.02 
Sodium (mmol·L-1)   0.92 (0.9-1.07) 0.08 
Note: CKD = Chronic Kidney Disease; OR = Odds Ratio; CI = Confidence Interval. 
 
 
Table 3. Multivariate predictors of all-cause mortality   
Characteristics HR (95% CI) P Value 
Demographics   
 Body mass index (kg·m2) 0.81 (0.71-0.9) <0.001 
Cardiac Autonomic Function   
 HRV total power spectrum (ms2) 0.98 (0.97-0.99) 0.02 
Cardiac Stress Test   
 Myocardial ischaemia 1.37 (1.17-1.81) 0.01 
Laboratory values    
 Albumin (mg·L-1) 0.86 (0.81-0.92) <0.001 
 eGFR (ml·mim-1·1.73m2) 1.01 (0.97-1.04) 0.39 
 Sodium (mmol·L-1) 0.92 (0.84-1.01) 0.07 
Note: HRV = Heart rate variability; eGFR = Estimated glomerular filtration rate. 
 
 
 
